Role of maximum androgen blockade in advanced prostate cancer
Androgen ablation is the mainstay treatment for advanced prostate cancer (PC). Researchers proposed that maximum androgen blockade (MAB) therapy with antiandrogen agent in combination with castration might result in a better outcome among patients with advanced PC. In the last two decades, numerous...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2009-01-01
|
| Series: | Indian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.indianjurol.com/article.asp?issn=0970-1591;year=2009;volume=25;issue=1;spage=47;epage=51;aulast=Ayyathurai |
| _version_ | 1811274408972517376 |
|---|---|
| author | Rajinikanth Ayyathurai Rosely De Los Santos Murugesan Manoharan |
| author_facet | Rajinikanth Ayyathurai Rosely De Los Santos Murugesan Manoharan |
| author_sort | Rajinikanth Ayyathurai |
| collection | DOAJ |
| description | Androgen ablation is the mainstay treatment for advanced prostate cancer (PC). Researchers proposed that maximum androgen blockade (MAB) therapy with antiandrogen agent in combination with castration might result in a better outcome among patients with advanced PC. In the last two decades, numerous trials and pooled data analyses were conducted to optimize the role of MAB in the treatment of metastatic PC. Non-steroidal antiandrogens administered as part of MAB proved to have a small (3%) survival benefit, however, the magnitude of this difference is of questionable clinical significance. Available evidence suggests that MAB should not be routinely offered to patients with metastatic PC, however, it should remain a reasonable option when discussing management. The standard first line treatment should be a monotherapy, consisting of orchiectomy or LHRH agonist. MAB still has a role as a short-term therapy (2-4 weeks). The ongoing large sample population based prospective studies may add new dimensions in the use of MAB in treatment of the prostate cancer in future. |
| first_indexed | 2024-04-12T23:18:22Z |
| format | Article |
| id | doaj.art-816b80105e7a432a88beeb1eefa329d7 |
| institution | Directory Open Access Journal |
| issn | 0970-1591 1998-3824 |
| language | English |
| last_indexed | 2024-04-12T23:18:22Z |
| publishDate | 2009-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Urology |
| spelling | doaj.art-816b80105e7a432a88beeb1eefa329d72022-12-22T03:12:36ZengWolters Kluwer Medknow PublicationsIndian Journal of Urology0970-15911998-38242009-01-01251475110.4103/0970-1591.45536Role of maximum androgen blockade in advanced prostate cancerRajinikanth AyyathuraiRosely De Los SantosMurugesan ManoharanAndrogen ablation is the mainstay treatment for advanced prostate cancer (PC). Researchers proposed that maximum androgen blockade (MAB) therapy with antiandrogen agent in combination with castration might result in a better outcome among patients with advanced PC. In the last two decades, numerous trials and pooled data analyses were conducted to optimize the role of MAB in the treatment of metastatic PC. Non-steroidal antiandrogens administered as part of MAB proved to have a small (3%) survival benefit, however, the magnitude of this difference is of questionable clinical significance. Available evidence suggests that MAB should not be routinely offered to patients with metastatic PC, however, it should remain a reasonable option when discussing management. The standard first line treatment should be a monotherapy, consisting of orchiectomy or LHRH agonist. MAB still has a role as a short-term therapy (2-4 weeks). The ongoing large sample population based prospective studies may add new dimensions in the use of MAB in treatment of the prostate cancer in future.http://www.indianjurol.com/article.asp?issn=0970-1591;year=2009;volume=25;issue=1;spage=47;epage=51;aulast=AyyathuraiAdvanced prostate cancermaximum androgen blockadetotal androgen blockade |
| spellingShingle | Rajinikanth Ayyathurai Rosely De Los Santos Murugesan Manoharan Role of maximum androgen blockade in advanced prostate cancer Indian Journal of Urology Advanced prostate cancer maximum androgen blockade total androgen blockade |
| title | Role of maximum androgen blockade in advanced prostate cancer |
| title_full | Role of maximum androgen blockade in advanced prostate cancer |
| title_fullStr | Role of maximum androgen blockade in advanced prostate cancer |
| title_full_unstemmed | Role of maximum androgen blockade in advanced prostate cancer |
| title_short | Role of maximum androgen blockade in advanced prostate cancer |
| title_sort | role of maximum androgen blockade in advanced prostate cancer |
| topic | Advanced prostate cancer maximum androgen blockade total androgen blockade |
| url | http://www.indianjurol.com/article.asp?issn=0970-1591;year=2009;volume=25;issue=1;spage=47;epage=51;aulast=Ayyathurai |
| work_keys_str_mv | AT rajinikanthayyathurai roleofmaximumandrogenblockadeinadvancedprostatecancer AT roselydelossantos roleofmaximumandrogenblockadeinadvancedprostatecancer AT murugesanmanoharan roleofmaximumandrogenblockadeinadvancedprostatecancer |